c-Met targeting therapeutic peptide - Genentech/PeptiDream
Latest Information Update: 06 Jan 2023
Price :
$50 *
At a glance
- Originator PeptiDream
- Developer Genentech; PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 06 Dec 2022 Preclinical trials in Unspecified in Japan (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Unspecified in USA (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)